Cargando…

Development and validation of a driving simulator for evaluating the residual effects of drugs on driving performance – sensitivity analysis using zopiclone as a positive control: Study Protocol Clinical Trial (SPIRIT Compliant)

INTRODUCTION: Drugs acting on the central nervous system (CNS), especially hypnotics, can impair driving. The US Food and Drug Administration started requiring pharmaceutical companies to evaluate the residual influence of CNS agents on driving performance to review their recommended doses. Although...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwata, Mari, Iwamoto, Kunihiro, Kambe, Daiji, Tachibana, Naoki, Ando, Masahiko, Ozaki, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220102/
https://www.ncbi.nlm.nih.gov/pubmed/32195934
http://dx.doi.org/10.1097/MD.0000000000019395
_version_ 1783533088177913856
author Iwata, Mari
Iwamoto, Kunihiro
Kambe, Daiji
Tachibana, Naoki
Ando, Masahiko
Ozaki, Norio
author_facet Iwata, Mari
Iwamoto, Kunihiro
Kambe, Daiji
Tachibana, Naoki
Ando, Masahiko
Ozaki, Norio
author_sort Iwata, Mari
collection PubMed
description INTRODUCTION: Drugs acting on the central nervous system (CNS), especially hypnotics, can impair driving. The US Food and Drug Administration started requiring pharmaceutical companies to evaluate the residual influence of CNS agents on driving performance to review their recommended doses. Although it is important for physicians to discuss automobile driving while on medication with patients to promote traffic safety, the package inserts of most CNS agents in Japan uniformly prohibit patients from driving. Although more evidence-based information regarding the effects of drugs on driving performance is needed, the current evaluation methods for driving performance abroad cannot be applied directly to Japanese drivers because of differences in traffic environments, laws, and constitutions. Therefore, we plan to establish a new driving simulator (DS) that would enable the next-day residual effects of drugs on driving performance to be examined. METHODS: In this double-blind, randomized, placebo-controlled, crossover trial, we plan to recruit 26 healthy Japanese males aged 21 to 64 years through advertisements. During the test periods, which will take place twice every other week, the participants will undergo a DS evaluation in the hospital for 2 days/1 night after the first and last doses of the study drug following 8 days of administration. The participants in the study drug group will take zopiclone 7.5 mg at bedtime on the first and eighth days in the hospital, and placebo on the other days. The DS evaluation consists of road tracking, car following, and harsh braking tests. The primary outcome is the standard deviation of lateral position (SDLP), which is a gold standard evaluation item, in the 60-min road-tracking test. The exploratory outcomes are other evaluation items in the DS tests, in the Karolinska Sleepiness Scale sleep questionnaire, and the Profile of Mood States Second Edition rating scale. The estimated difference in the SDLP between the zopiclone and placebo groups will then be calculated. TRIAL REGISTRATION: This study was registered at ClinicalTrials.gov NCT 04108351, on September 30, 2019. Ethics approval was obtained from the Ethics Committee at Hakata Clinic and the Nagoya University Medical School Hospital Bioethics Review Committee.
format Online
Article
Text
id pubmed-7220102
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-72201022020-06-15 Development and validation of a driving simulator for evaluating the residual effects of drugs on driving performance – sensitivity analysis using zopiclone as a positive control: Study Protocol Clinical Trial (SPIRIT Compliant) Iwata, Mari Iwamoto, Kunihiro Kambe, Daiji Tachibana, Naoki Ando, Masahiko Ozaki, Norio Medicine (Baltimore) 3700 INTRODUCTION: Drugs acting on the central nervous system (CNS), especially hypnotics, can impair driving. The US Food and Drug Administration started requiring pharmaceutical companies to evaluate the residual influence of CNS agents on driving performance to review their recommended doses. Although it is important for physicians to discuss automobile driving while on medication with patients to promote traffic safety, the package inserts of most CNS agents in Japan uniformly prohibit patients from driving. Although more evidence-based information regarding the effects of drugs on driving performance is needed, the current evaluation methods for driving performance abroad cannot be applied directly to Japanese drivers because of differences in traffic environments, laws, and constitutions. Therefore, we plan to establish a new driving simulator (DS) that would enable the next-day residual effects of drugs on driving performance to be examined. METHODS: In this double-blind, randomized, placebo-controlled, crossover trial, we plan to recruit 26 healthy Japanese males aged 21 to 64 years through advertisements. During the test periods, which will take place twice every other week, the participants will undergo a DS evaluation in the hospital for 2 days/1 night after the first and last doses of the study drug following 8 days of administration. The participants in the study drug group will take zopiclone 7.5 mg at bedtime on the first and eighth days in the hospital, and placebo on the other days. The DS evaluation consists of road tracking, car following, and harsh braking tests. The primary outcome is the standard deviation of lateral position (SDLP), which is a gold standard evaluation item, in the 60-min road-tracking test. The exploratory outcomes are other evaluation items in the DS tests, in the Karolinska Sleepiness Scale sleep questionnaire, and the Profile of Mood States Second Edition rating scale. The estimated difference in the SDLP between the zopiclone and placebo groups will then be calculated. TRIAL REGISTRATION: This study was registered at ClinicalTrials.gov NCT 04108351, on September 30, 2019. Ethics approval was obtained from the Ethics Committee at Hakata Clinic and the Nagoya University Medical School Hospital Bioethics Review Committee. Wolters Kluwer Health 2020-03-20 /pmc/articles/PMC7220102/ /pubmed/32195934 http://dx.doi.org/10.1097/MD.0000000000019395 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 3700
Iwata, Mari
Iwamoto, Kunihiro
Kambe, Daiji
Tachibana, Naoki
Ando, Masahiko
Ozaki, Norio
Development and validation of a driving simulator for evaluating the residual effects of drugs on driving performance – sensitivity analysis using zopiclone as a positive control: Study Protocol Clinical Trial (SPIRIT Compliant)
title Development and validation of a driving simulator for evaluating the residual effects of drugs on driving performance – sensitivity analysis using zopiclone as a positive control: Study Protocol Clinical Trial (SPIRIT Compliant)
title_full Development and validation of a driving simulator for evaluating the residual effects of drugs on driving performance – sensitivity analysis using zopiclone as a positive control: Study Protocol Clinical Trial (SPIRIT Compliant)
title_fullStr Development and validation of a driving simulator for evaluating the residual effects of drugs on driving performance – sensitivity analysis using zopiclone as a positive control: Study Protocol Clinical Trial (SPIRIT Compliant)
title_full_unstemmed Development and validation of a driving simulator for evaluating the residual effects of drugs on driving performance – sensitivity analysis using zopiclone as a positive control: Study Protocol Clinical Trial (SPIRIT Compliant)
title_short Development and validation of a driving simulator for evaluating the residual effects of drugs on driving performance – sensitivity analysis using zopiclone as a positive control: Study Protocol Clinical Trial (SPIRIT Compliant)
title_sort development and validation of a driving simulator for evaluating the residual effects of drugs on driving performance – sensitivity analysis using zopiclone as a positive control: study protocol clinical trial (spirit compliant)
topic 3700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220102/
https://www.ncbi.nlm.nih.gov/pubmed/32195934
http://dx.doi.org/10.1097/MD.0000000000019395
work_keys_str_mv AT iwatamari developmentandvalidationofadrivingsimulatorforevaluatingtheresidualeffectsofdrugsondrivingperformancesensitivityanalysisusingzopicloneasapositivecontrolstudyprotocolclinicaltrialspiritcompliant
AT iwamotokunihiro developmentandvalidationofadrivingsimulatorforevaluatingtheresidualeffectsofdrugsondrivingperformancesensitivityanalysisusingzopicloneasapositivecontrolstudyprotocolclinicaltrialspiritcompliant
AT kambedaiji developmentandvalidationofadrivingsimulatorforevaluatingtheresidualeffectsofdrugsondrivingperformancesensitivityanalysisusingzopicloneasapositivecontrolstudyprotocolclinicaltrialspiritcompliant
AT tachibananaoki developmentandvalidationofadrivingsimulatorforevaluatingtheresidualeffectsofdrugsondrivingperformancesensitivityanalysisusingzopicloneasapositivecontrolstudyprotocolclinicaltrialspiritcompliant
AT andomasahiko developmentandvalidationofadrivingsimulatorforevaluatingtheresidualeffectsofdrugsondrivingperformancesensitivityanalysisusingzopicloneasapositivecontrolstudyprotocolclinicaltrialspiritcompliant
AT ozakinorio developmentandvalidationofadrivingsimulatorforevaluatingtheresidualeffectsofdrugsondrivingperformancesensitivityanalysisusingzopicloneasapositivecontrolstudyprotocolclinicaltrialspiritcompliant